Synthesis of Small Molecule CDC25 Phosphatases Inhibitors
Overview
Authors
Affiliations
A targeted library of small molecules has been prepared to optimize the biological activity of BN82002, our initial lead compound, recently described as an original inhibitor of CDC25 phosphatases. Some of these compounds inhibit CDC25 in the micromolar range and therefore reinforce the interest of CDC25 as an anticancer target.
A Comprehensive Overview of the Developments of Cdc25 Phosphatase Inhibitors.
Abdelwahab A, El-Sawy E, Hanna A, Bagrel D, Kirsch G Molecules. 2022; 27(8).
PMID: 35458583 PMC: 9031484. DOI: 10.3390/molecules27082389.
Aliotta F, Nasso R, Rullo R, Arcucci A, Avagliano A, Simonetti M J Enzyme Inhib Med Chem. 2020; 35(1):1866-1878.
PMID: 32990107 PMC: 7580834. DOI: 10.1080/14756366.2020.1819257.
Pharmacophore-guided discovery of CDC25 inhibitors causing cell cycle arrest and tumor regression.
Kabakci Z, Kappeli S, Cantu C, Jensen L, Konig C, Toggweiler J Sci Rep. 2019; 9(1):1335.
PMID: 30718768 PMC: 6362118. DOI: 10.1038/s41598-019-38579-7.
Evain-Bana E, Schiavo L, Bour C, Lanfranchi D, Berardozzi S, Ghirga F J Enzyme Inhib Med Chem. 2016; 32(1):113-118.
PMID: 27774816 PMC: 6010111. DOI: 10.1080/14756366.2016.1238364.
Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.
Pericolini E, Gabrielli E, Bistoni G, Cenci E, Perito S, Chow S PLoS One. 2010; 5(9):e12720.
PMID: 20856869 PMC: 2939064. DOI: 10.1371/journal.pone.0012720.